Cambrooke Therapeutics
Latest round
- Series C
Last raised
- Apr 2016
Total raised
- $8M
Investors
- 2
About Cambrooke Therapeutics
Cambrooke Therapeutics, Inc.Cambrooke Therapeutics, Inc. was founded in 2000 in Ayer, US, and is known for developing medical nutrition products., Inc. in November 2017 for USD 64 mn.Cambrooke Therapeutics, Inc. specializes in advanced medical nutrition, offering a range of nutritional therapeutic options designed to address specific chronic medical needs. Their core product offerings include specialized formulas such as Glytactin and Tylactin, which are tailored for patients with conditions like Phenylketonuria (PKU) and Maple Syrup Urine Disease (MSUD). These products aim to improve patient satisfaction and clinical outcomes by providing effective dietary management solutions that allow users to maintain a balanced diet while adhering to their medical restrictions. The company serves a diverse clientele, including healthcare providers, hospitals, and patients across various geographical markets such as the United States, Canada, and select international regions.Cambrooke Therapeutics, Inc. generates revenue through direct-to-consumer sales as well as partnerships with healthcare professionals and institutions. Their business model involves the distribution of specialized medical nutrition products, which may be purchased directly by patients or prescribed by healthcare providers. This dual channel allows the company to reach both end-users and institutional clients effectively. Flagship products such as Tylactin RTD and Glytactin RTD facilitate recurring purchases due to their necessity in managing specific dietary restrictions. The pricing structure encompasses individual product sales, potentially offering different pricing tiers based on the product type or packaging.Following the acquisition in November 2017, Cambrooke Therapeutics, Inc. The company is focused on designing new medical nutrition products aimed at addressing broader dietary needs and expanding its reach into additional international markets by 2025.
Who invested in Cambrooke Therapeutics
2 investors across 2 rounds
See all investors in Cambrooke Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cambrooke Therapeutics
Who invested in Cambrooke Therapeutics?
Cambrooke Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cambrooke Therapeutics raised?
Cambrooke Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Cambrooke Therapeutics last raise money?
Cambrooke Therapeutics's most recent round on record is a Series C, in Apr 2016.
What does Cambrooke Therapeutics do?
Cambrooke Therapeutics is a healthcare company.
Where is Cambrooke Therapeutics headquartered?
Cambrooke Therapeutics is headquartered in Ayer, US.
Which VCs invest in companies like Cambrooke Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Kleiner Perkins and Lightspeed Venture Partners back healthcare companies at Cambrooke Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare startups at Series C
Raising like Cambrooke Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.